Cederström, Sofia
Lundman, Pia
Alfredsson, Joakim
Hagström, Emil
Ravn-Fischer, Annica
Söderberg, Stefan
Yndigegn, Troels
Tornvall, Per
Jernberg, Tomas
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 16 March 2023
Accepted: 19 July 2023
First Online: 27 July 2023
Competing interests
: JA reports payment for lectures from AstraZeneca, Bayer, Boehringer-Ingelheim, MSD and Novartis, and reimbursement for advisory board participation from AstraZeneca and Novartis. EH received research grant funding from Amgen and Pfizer, payment or honoraria for lectures or presentations from Amarin, Amgen, AstraZeneca, Bayer, Novartis and NovoNordisk, payment for advisory board participation from Amarin, Amgen, Novartis and Sanofi, and institutional payment as national coordinator of DalCore: DAL301 DalGene; R1500-CL-1643 and Aegis II/Perfuse. ARF reports payment for lectures from Amarin, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Orion Pharma, NovoNordisk, Pfizer and Sanofi, and payment for advisory board participation from Amarin, Amgen, Boehringer-Ingelheim and Sanofi. SS reports speaker’s honoraria and advisory board participation for Actelion Ltd. The other authors did not report any conflicts of interest.